Organization
University Cancer Center Germany
1 abstract
Abstract
A randomized, open-label phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophagogastric junction and high immune responsiveness: The IKF633/DANTE trial, a trial of AIO in collaboration with SAKK.Org: University Cancer Center Germany, St. Anna Hospital Herne, RKH-Clinics Ludwigsburg, University Hospital Ulm, Charité-University madicine Berlin,